Abstract:Objective To verify the efficacy and safety of intravesical instillation of Cystistat in reducing complications caused by intravesical chemotherapy after TUR-BT in non-muscle invasive bladder cancer patients. Methods One hundred and twenty patients who met the inclusion/exclusion criteria were enrolled into this multi-centered, randomized and blank controlled clinical study. Selected patients were randomized into the observation group and control group. TUR-BT was carried out in both groups followed by pirarubicin (THP) and Cystistat intravesical instillation in the observation group, and THP intravesical instillation alone in control group. Visual analog scale (VAS) was used as the primary efficacy variable. The secondary efficacy variables were assessments of hematuria and bladder irritation symptoms. Adverse events, laboratory tests and changes of vital signs before and after treatment were strictly observed during observation to evaluate the efficacy and safety of Cystistat.Results Demographics and baseline characteristics were comparable in both groups. The differences and the improvement rate of VAS score in the 2 groups were significant, both P＜0.01. The changes of VAS score and the improvement rate before and after treatment were (2. 24±1.70) and (92. 92±14.76) % in observation group and (0. 70±1.82) and (20. 59±87.34)% in control group respectively. According to the covariance analysis, there were significant differences in changes of VAS score between the observation group and the control group. Also, the improvement rate of VAS score was significant from visit 2. The urine frequency decreased from 9.06±4.09 to 6. 69±2.89 in observation group and increased from 8. 85±3. 32 to 10. 15±4.40 in control group, P＜0.01. There were also significant differences in changes of nocturia before and after treatment between these two groups (P＜0.01), the nocturia decreased from 2. 88±1.74 to 1. 47±1.62 in observation group and 3. 22±2.30 to 2.91±1.73 in control group, respectively. The changes of WHO assessment for hematuria,urgency and dysuria were not significantly different between the 2 groups. No Cystistat related adverse event was observed. Conclusions Cystistat combined instillation can significantly improve the VAS score of patients with chemotherapeutic agent instillation. Relief of bladder pain, frequency and nocturia are more rapidly and more durable in Cystistat combined instillation group. The improvement is more effective in patients with a high VAS score. Cystistat instillation with chemotherapeutics agents is both well tolerated and safe.

Clinical observation of intravesical chemotherapy with pirarubicin reconstituted with different solvents following TUR-Bt

Combination of Cystistat and Pirarubicin Intravesical Instillation in Reducing Intravesical Chemotherapy Complications: a Multi-Center Clinical Study

Single-dose Instillations of Epirubicin As Prophylaxis for Recurrence of Superficial Bladder Tumors:A Prospective Randomized Controlled Study

Observation of Immediate Intravesical Instillation of Pirarubicin in Preventing Non-Muscle-Invasive Bladder Cancer Relapse after Transurethral Resection of Bladder Tumor

Therapeutic Observation of Intravesical Instillation with Pirarubicin in the Prophylaxis of Cystitis Glandularis Recurrence

Effect on Prophase Intravesical Instillation of Pirarubicin for Preventing Recurrence of Bladder Cancer

Investigation on the Management of Pirarubicin As the Intravesical Chemotherapy for Preventing Post-Turbt Recurrence of the Superficial Bladder Cancer

Comparison of the Clinical Outcome of Instant Single Intravesical Instillation of Pirarubicin and Multiple Instillations after TUR-Bt for Preventing Recurrence of Non Muscle Invasive Bladder Cancer

Preoperative and Postoperative Intravesical Instillation Versus Alone Postoperative Intravesical Instillation of Pirarubicin for the Prevention of Postoperative Recurrence of Non-Muscle Invasive Bladder Cancer: a Prospective Randomized Controlled Trial

Prevention of recurrence of bladder cancer by postoperatively intravesical instillation of pirarubicin

The clinical investigation of different intravesical instillation of chemotherapy after transurethral resection of bladder tumors for the treatment of superficial bladder cancer

Efficacy Of Immediate Instillation Combined With Regular Instillations Of Pirarubicin For Ta And T1 Transitional Cell Bladder Cancer After Transurethral Resection: A Prospective, Randomized, Multicenter Study

[Mechanism of Intravesical Instillation of Pirarubicin for Preventing Recurrence of Non-Muscle Invasive Bladder Cancer].

Intravesical Instillation of Pirarubicin for Preventing Postoperative Recurrence of Superficial Bladder Cancer in 132 patients

Single-dose intra-arterial infusion chemotherapy for refractory bladder cancer after transurethral resection of bladder tumor: Report of 12 cases

Effects of Intravenous Chemotherapy after TURBT for High-Risk Nonmuscle Invasive Bladder Cancer: Results of a Retrospective Study

Evidence-based pharmacoeconomic research of pirarubicin and epirubicin as prophylaxis for recurrence in patients with superficial bladder tumors by bladder instillation after transurethral resection of a bladder tumor

Combination of Hyperthermia and Intravesical Chemotherapy for the Treatment of Pt1 Stage Bladder Cancer: A Retrospectively Clinical Study.

Early Intravesical Chemotherapy after Transurethral Resection of Non-Muscle-Invasive Bladder Cancer: A Systematic Review

Intravesical Instillation of Pirarubicin(thp) for Preventing Postoperative Recurrence of Superficial Bladder Cancer

Intravesical Instillation of Epirubicin Combined with BCG to Prevent the Recurrence of Bladder Cancer after Surgical Management